Forest's Daxas Is Safe And Is Effective, But Not Both, Panel Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
A divided Pulmonary-Allergy Drugs Advisory Committee finds that Forest's COPD drug has been shown to be safe and to be effective in separate votes, but finds the overall risk-benefit balance lacking.
You may also be interested in...
Daxas Approved In EU With Narrow Indication
Nycomed's drug gets the green light to treat severe COPD with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator treatment.
Daxas Approved In EU With Narrow Indication
Nycomed's drug gets the green light to treat severe COPD with chronic bronchitis in adult patients with a history of frequent exacerbations, as an add-on to bronchodilator treatment.
Daxas REMS May Be Key To Approval After "Complete Response" Letter
FDA seems more likely to approve the COPD if labeling is restricted to moderate-to-severe patients with chronic bronchitis, but Forest will probably need to show that it can limit use.